RecruitingNot ApplicableNCT07112287

Germline Testing for Predisposition to Myeloid Malignancies

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

Sponsor

Christopher Reilly

Enrollment

200 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Genetic Predisposition to Disease Myeloid Malignancy Myeloid Hematological Malignancies

Summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called MyeloGen Gene Panel for people with genetic predisposition to disease, myeloid hematological malignancies, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMyeloGen Gene Panel

The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07112287

Related Trials

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

NCT065944451 location

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

NCT076192874 locations

Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

NCT072630741 location

Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure

NCT070181281 location

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

NCT0450112012 locations